BAC B.V. The company provides affinity purification products and services for the biopharmaceutical market. Our products are used for drug discovery upto manufacturing of biopharmaceuticals and are based on a proprietary platform technology, integrating affinity ligand discovery, manufacturing and immobilization of single domain antibodies derived from Camelids. Our products are sold worldwide and we have over 10 research products on the market for both drug discovery and purification and 5 products for large scale manufacturing. In addition, our service to develop affinity products has been used by renowned (bio)pharmaceutical companies. In 2005 the company completed an external private financing round to enable the company to continue development of new solutions for lab scale separations and to advance its lead products toward launch for large scale use in pharmaceutical processes. In 2008 the company completed a Series B financing round to support the further development of its own pipeline of affinity products. The company has an extensive IP portfolio to support the products and technology, in addition to a R&D lab and manufacturing facilities for its products.